Unknown PHASE2 INTERVENTIONAL NCT00093522

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

A Phase II Pilot Study of Tumor-Loaded Dendritic Cells Alone or Following a Non-Myeloablative Conditioning Regimen in Patients With Metastatic Renal Cell Carcinoma

Sponsor: St. Luke's Medical Center

Conditions Kidney Cancer

Interventions autologous tumor cell vaccine conventional surgery fludarabine phosphate keyhole limpet hemocyanin therapeutic autologous dendritic cells

Updated 5 times since 2017 Last updated: Dec 18, 2013 Started: Aug 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Kidney Cancer and is currently ongoing. St. Luke's Medical Center leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

St. Luke's Medical Center

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milwaukee, United States